vTv Therapeutics Company Profile (NASDAQ:VTVT)

vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."

vTv Therapeutics Inc. (NASDAQ:VTVT) posted its earnings results on Wednesday, August, 2nd. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.02. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.19 million. View vTv Therapeutics' Earnings History.

vTv Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for vTv Therapeutics.

4 analysts have issued 12 month price objectives for vTv Therapeutics' shares. Their predictions range from $13.00 to $24.00. On average, they anticipate vTv Therapeutics' stock price to reach $16.50 in the next twelve months. View Analyst Ratings for vTv Therapeutics.

Here are some recent quotes from research analysts about vTv Therapeutics stock:

• 1. According to Zacks Investment Research, "vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company's drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. " (8/8/2017)
• 2. Canaccord Genuity analysts commented, "We reiterate our BUY. Pivotal Ph3 azeliragon Alzheimer trials enrollment complete: Part A to deliver data in 1H18 and Part B in 2H. Mgmt. announced Ph3 STEADFAST Part B completed enrollment, including 20-25% ROW pts. Conducted under Special Protocol Assessment, STEADFAST is an 18-month, randomized, double-blind, placebo-controlled study assessing oral, once- daily azeliragon’s effect on cognitive/functional decline in 400 mild Alzheimer’s Disease (AD) pts. on standard-of-care (SOC; acetylcholinesterase inhibitor and/or memantine). Co-primary endpoints include change in AD Assessment Scale-cognitive subscale (ADAS- Cog11) and Clinical Dementia Rating Scale Sum of Boxes (CDR-sb). Part A completed enrollment in mid-16. In a Ph2b trial assessing SOC +/- 5mg azeliragon at 18 months, daily azeliragon was well-tolerated and had significantly lower ADAS-Cog11 and CDR-sb score decline, with greater benefit in mild patients, and significantly fewer psychiatric events." (8/4/2017)

Some companies that are related to vTv Therapeutics include Gemphire Therapeutics (GEMP), Affimed N.V. (AFMD), Lipocine (LPCN), Pfenex (PFNX), ADMA Biologics (ADMA), Intec Pharma (NTEC), ProNAi Therapeutics (SRRA), Ergomed PLC (ERGO), Synthetic Biologics (SYN), Dicerna Pharmaceuticals (DRNA), ImmuPharma PLC (IMM), Flex Pharma (FLKS), Dipexium Pharmaceuticals (PLXP), Motif Bio PLC (MTFB), Leap Therapeutics (LPTX), Rexahn Pharmaceuticals (RNN), Endocyte (ECYT) and Proteostasis Therapeutics (PTI).

vTv Therapeutics' management team includes the folowing people:

• Jeffrey B. Kindler, Executive Chairman of the Board
• Stephen L. Holcombe, President, Chief Executive Officer
• Rudy C. Howard CPA, Chief Financial Officer, Executive Vice President
• Larry Douglas Altstiel M.D. Ph.D., Chief Medical Officer
• Steven M. Cohen, Director
• Paul M. Meister, Director
• Paul G. Savas, Director
• Howard L. Weiner, Director
• John A. Fry, Independent Director

(VTVT) raised $125 million in an initial public offering (IPO) on Thursday, July 30th 2015. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Piper Jaffray and Stifel served as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

vTv Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include MACANDREWS & FORBES INC. (78.10%), Franklin Resources Inc. (2.74%), Sphera Funds Management LTD. (0.91%), Ameriprise Financial Inc. (0.81%), Vanguard Group Inc. (0.78%) and Candriam Luxembourg S.C.A. (1.44%). Company insiders that own vTv Therapeutics stock include Noel Joseph Spiegel, Paul G Savas and Ronald O Perelman. View Institutional Ownership Trends for vTv Therapeutics.

vTv Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Vanguard Group Inc., Bank of New York Mellon Corp and Northern Trust Corp. View Insider Buying and Selling for vTv Therapeutics.

vTv Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc. and State Street Corp. Company insiders that have bought vTv Therapeutics stock in the last two years include Noel Joseph Spiegel, Paul G Savas and Ronald O Perelman. View Insider Buying and Selling for vTv Therapeutics.

Shares of vTv Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of vTv Therapeutics stock can currently be purchased for approximately $4.78.